Immunosuppression News and Research

RSS
Immunosuppression involves an act that reduces the activation or efficacy of the immune system. Some portions of the immune system itself have immuno-suppressive effects on other parts of the immune system, and immunosuppression may occur as an adverse reaction to treatment of other conditions.
Recent developments at Burnham Institute for Medical Research

Recent developments at Burnham Institute for Medical Research

Extending hepatitis C treatment for liver transplant patients results in sustained viral clearance

Extending hepatitis C treatment for liver transplant patients results in sustained viral clearance

Race of kidney donors may affect the survival rates of transplant recipients

Race of kidney donors may affect the survival rates of transplant recipients

Isotechnika Pharma develops portfolio of NICAMs with potent cyclophilin inhibition

Isotechnika Pharma develops portfolio of NICAMs with potent cyclophilin inhibition

Patients with Inflammatory Bowel Disease may be at risk for developing non-melanoma skin cancer

Patients with Inflammatory Bowel Disease may be at risk for developing non-melanoma skin cancer

ISHLT Infectious Disease Council issues new H1N1 advisory for cardiothoracic transplantation programs

ISHLT Infectious Disease Council issues new H1N1 advisory for cardiothoracic transplantation programs

Practical guidance for cardiothoracic transplant programs in view of H1N1 flu pandemic

Practical guidance for cardiothoracic transplant programs in view of H1N1 flu pandemic

Peregrine Pharmaceuticals reports positive results from Phase II trial of bavituximab

Peregrine Pharmaceuticals reports positive results from Phase II trial of bavituximab

Novartis' Tasigna capsules meets primary endpoint in comparison trial with Gleevec

Novartis' Tasigna capsules meets primary endpoint in comparison trial with Gleevec

Less expensive anti-rejection drug as effective as more expensive drug, says study

Less expensive anti-rejection drug as effective as more expensive drug, says study

Results from Phase 2 clinical study of LCP-Tacro tablets in stable liver transplant patients announced

Results from Phase 2 clinical study of LCP-Tacro tablets in stable liver transplant patients announced

Enzo Biochem and NEI join to conduct a human clinical trial of Enzo’s chronic autoimmune uveitis therapeutic

Enzo Biochem and NEI join to conduct a human clinical trial of Enzo’s chronic autoimmune uveitis therapeutic

80-unit patient housing facility for cancer patients and families

80-unit patient housing facility for cancer patients and families

Toll-like receptors that activate immune cells being developed as alternative cure to cancer

Toll-like receptors that activate immune cells being developed as alternative cure to cancer

AST meeting to review most recent developments in the field of organ transplantation

AST meeting to review most recent developments in the field of organ transplantation

Phase 2 MS clinical trial data continues to show durable reductions in relapse rate

Phase 2 MS clinical trial data continues to show durable reductions in relapse rate

Human neural stem cells to treat Pelizaeus-Merzbacher Disease

Human neural stem cells to treat Pelizaeus-Merzbacher Disease

AST scientific conference to emphasize on immunosuppression and tolerance

AST scientific conference to emphasize on immunosuppression and tolerance

Rite Aid pharmacies to offer regular seasonal flu shots throughout the flu season

Rite Aid pharmacies to offer regular seasonal flu shots throughout the flu season

LifeCycle Pharma terminates contract agreement with CEO

LifeCycle Pharma terminates contract agreement with CEO

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.